<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757571</url>
  </required_header>
  <id_info>
    <org_study_id>RS10/2021</org_study_id>
    <nct_id>NCT04757571</nct_id>
  </id_info>
  <brief_title>The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients</brief_title>
  <official_title>The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients. A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sadat City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sadat City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among three MAPK families, paroxetine was found to be able to decrease the phosphorylation of&#xD;
      ERK. It was reported that paroxetine attenuates the symptoms of collage induced arthritis&#xD;
      rats due to its inhibitory effect on T cell activation and infiltration to synovial tissue&#xD;
      via suppression of ERK pathway. This study aimed to evaluate the therapeutic efficacy of&#xD;
      paroxetine in rheumatoid arthritis. Paroxetine prevents the joint inflammation which is at&#xD;
      the very early stage. paroxetine could inhibit GRK2 with selectivity over other GRKs.&#xD;
      Medications developed for maintaining the immunologic equilibrium. such as GRK2 inhibitors,&#xD;
      will be the novel trends in RA treatment that could avoid the adverse side effects that are&#xD;
      common with current treatment options.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR 20% improvement criteria (ACR20) response rate</measure>
    <time_frame>week 12</time_frame>
    <description>based on tender and swollen joint counts, patient's assessment of pain, patient and physician global assessment of arthritis, Health Assessment Questionnaire Disability Index (HAQ DI), and CRP level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 &amp; ACR70 response rate</measure>
    <time_frame>week 12</time_frame>
    <description>based on tender and swollen joint counts, patient's assessment of pain, patient and physician global assessment of arthritis, Health Assessment Questionnaire Disability Index (HAQ DI), and CRP level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity scale in 28 joints (DAS-28)</measure>
    <time_frame>week 12</time_frame>
    <description>Scale assessing severity of rheumatoid arthritis based on number of tender, swollen joints, erythrocyte sedimentation rate (ESR) levels, and patient self-assessment of his condition (global health assessment). Whereas &quot;28&quot; describes the number of different joints including in the measurement: proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2), knees (2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GRK2 expression</measure>
    <time_frame>week 12</time_frame>
    <description>GRK2 expression in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α</measure>
    <time_frame>week 12</time_frame>
    <description>Serum level Tumor necrosis factor- alpha (TNF-α)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inteleukins</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum levels of Interleukins (IL) IL-17, IL-1β , IL-6 &amp; IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum level of C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Adverse effects</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse effect incidence: adverse effect will be reported by patients or their caregivers and recorded by investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxetine 20 mg daily plus standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet daily plus standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Paroxetine 20 mg tablet plus standard therapy</description>
    <arm_group_label>Paroxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet plus standard therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Patients with active rheumatoid arthritis based on DAS28 score. Patients received the&#xD;
        standard therapy (i.e. one or more conventional DMARDs) for at least three months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to metformin.&#xD;
&#xD;
          -  Patients who have a prior diagnosis with diabetes mellitus.&#xD;
&#xD;
          -  Patients receive metformin for any other indications.&#xD;
&#xD;
          -  Patients with congestive heart failure.&#xD;
&#xD;
          -  Patients with a history of myocardial infarction.&#xD;
&#xD;
          -  Patients with severe anemia.&#xD;
&#xD;
          -  Patients with active infections or other inflammatory diseases.&#xD;
&#xD;
          -  Patients receiving biological therapy.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Patients with impaired liver functions.&#xD;
&#xD;
          -  Patients with impaired kidney functions (serum creatinine concentrations ≥1.5 and ≥1.4&#xD;
             mg/dL in males and females respectively).&#xD;
&#xD;
          -  Patients with malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Pharmacy</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufia</state>
        <zip>13829</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud S Abdallah, PhD</last_name>
      <phone>01063340887</phone>
      <email>Mahmoud.samy@fop.usc.edu.eg</email>
    </contact>
    <contact_backup>
      <phone>+201063340887</phone>
      <email>Mahmoud.samy@fop.usc.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sadat City University</investigator_affiliation>
    <investigator_full_name>Mahmoud Samy Abdallah</investigator_full_name>
    <investigator_title>Lecturer of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

